Psychiatry & Neurology, Neuromuscular Medicine · O Fallon, IL
NPI
1639481914
Since 2010
Specialty
Psychiatry & Neurology, Neuromuscular Medicine
Code 2084N0008X
Group practices
1
Medicare group memberships
Hospitals
6
Hospital affiliations
3 Saint Elizabeth Blvd
O Fallon, IL, 62269
Phone (618) 641-5803
Groups this clinician bills Medicare through
Medicare paid, 2024
$419K
40,102 services
Medicare patients, 2024
769
Average age 73
Drug cost, 2024
$3.9M
2,771 prescriptions
Company payments, 2025
$211K
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Raghav Govindarajan was code J0585 (injection, onabotulinumtoxina, 1 unit), 35,580 times for 94 patients. In total Raghav Govindarajan billed 40,102 services in 40 codes, and Medicare paid $419K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 35,580 | 94 | $4.98 | $177K |
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 1,750 | 13 | $4.10 | $7,174 |
| 99213 Office E&M - Established | Office | 518 | 337 | $65.84 | $34K |
| 95886 Electrical Nerve Conductivity | Office | 334 | 258 | $74.37 | $25K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 256 | 26 | $0.70 | $178 |
| 95874 Musculoskeletal | Office | 202 | 76 | $56.47 | $11K |
| 99214 Office E&M - Established | Office | 197 | 151 | $99.71 | $20K |
| 95913 Electrical Nerve Conductivity | Office | 168 | 167 | $210.60 | $35K |
| 64644 Musculoskeletal | Office | 145 | 56 | $129.07 | $19K |
| 64645 Musculoskeletal | Office | 118 | 46 | $102.81 | $12K |
| 95816 Neurologic | Facility | 98 | 85 | $44.32 | $4,343 |
| 95910 Electrical Nerve Conductivity | Office | 96 | 95 | $128.96 | $12K |
| 95813 Neurologic | Facility | 90 | 89 | $62.02 | $5,582 |
| 64615 Musculoskeletal | Office | 74 | 29 | $128.33 | $9,496 |
| 64616 Musculoskeletal | Office | 69 | 28 | $167.73 | $12K |
By year: 2022 $291K for 27,298 services; 2023 $391K for 37,729 services; 2024 $419K for 40,102 services.
Medicare prescription drug claims, 2024
In 2024, the drug Raghav Govindarajan prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 458 prescriptions and refills. In total Raghav Govindarajan wrote 2,771 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 458 | 766 | 84 | $11K |
| Levetiracetam Generic | 268 | 418 | 58 | $6,525 |
| Donepezil Hcl Generic | 165 | 323 | 41 | $1,658 |
| Gabapentin Generic | 143 | 184 | 40 | $2,103 |
| Memantine Hcl Generic | 114 | 205 | 25 | $2,588 |
| Ubrelvy Ubrogepant | 113 | 115 | 40 | $173K |
| Qulipta Atogepant | 97 | 101 | 18 | $119K |
| Lacosamide Generic | 78 | 85 | 13 | $8,052 |
| Prednisone Generic | 73 | 97 | 13 | $285 |
| Lamotrigine Generic | 64 | 108 | 11 | $933 |
| Baclofen Generic | 60 | 69 | 12 | $379 |
| Nurtec Odt Rimegepant Sulfate | 55 | 55 | 13 | $107K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 50 | 88 | 11 | $2,362 |
| Quetiapine Fumarate Generic | 46 | 76 | 16 | $787 |
| Aimovig Autoinjector Erenumab-Aooe | 44 | 48 | Under 11 | $36K |
Brand drugs: 554 claims; generic drugs: 2,198 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Raghav Govindarajan $211K ($211K in general payments such as food, travel and fees) from 14 companies. The largest payer was Argenx US, Inc. with $83K.
| Company | Payments | Amount |
|---|---|---|
| Argenx US, Inc. ARGX | 91 | $83K |
| Alexion Pharmaceuticals, Inc. AZN | 19 | $26K |
| Axsome Therapeutics, Inc. AXSM | 19 | $26K |
| Janssen Biotech, Inc. JNJ | 18 | $16K |
| Pfizer Inc. PFE | 53 | $16K |
| Abbvie Inc. ABBV | 26 | $12K |
| Amgen Inc. AMGN | 12 | $12K |
| UCB, Inc. UCB.BR | 13 | $12K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $6,249 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. 4578.T | 1 | $1,500 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.